-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 12, the team of Professor Chong Chen and Professor Liu Yu of the State Key Laboratory of Biotherapy and the team of Professor Wei Qiang of the Department of Urology published a research paper Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for, in Cancer Cell (IF:38.
Dr.
Although more and more new tumor treatment programs such as targeted therapy and immunotherapy have entered the clinic in recent years, chemotherapy is still the main means
Muscle-invasive bladder cancer (MIBC) is the most common urinary malignancy, and cisplatin-based chemotherapy is the first-line treatment for
In this study, the team constructed a primary and in situ MIBC mouse model
To resolve the molecular mechanisms of MIBC chemotherapy resistance, the team constructed a molecular pathway
The team then discovered the therapeutic target of drug-resistant MIBC squamous differentiation through multi-omics analysis, histoproteinase CTSH
Through pathological analysis, differentiation marker staining, and analysis of single cell omics, transcriptome, proteomics and other analysis, the team found that after knockout CTSH or E64 treatment, the MIC cells that had already shown a certain degree of squamous differentiation underwent terminal squamous differentiation
The scientific significance and innovation of this work lies in the fact that from the construction of a novel precise mouse model of bladder cancer, the new characteristics of the lineage plasticity of MIBC-acquired chemotherapy-resistant semi-squamous differentiation are revealed, and a new strategy
The research team expects CTSH to serve as a new molecular marker for the clinical treatment of chemotherapy-resistant bladder cancer patients, and also expects that E64 can be used as a new treatment to improve the survival time and quality
In recent years, Professor Wei Qiang's team of Urology has worked closely with the teams of Professor Chen Chong and Professor Liu Yu of the State Key Laboratory of Biotherapy to study the mechanism of chemotherapy resistance in bladder cancer, the development of new targets for treatment, and the verification
Original link: https://doi.
